f Response to the Letter to the Editor: Epicardial Adipose Tissue Modulation: A New Horizon for Sodium-glucose Cotransporter 2 Inhibitors

References

1. TheofilisP. OikonomouE. VlachakisP.K. Sodium-glucose cotransporter 2 inhibitors and changes in epicardial adipose tissue: A systematic literature review and meta-analysis.Curr. Vasc. Pharmacol.202523320421210.2174/0115701611330060241204062248 39819408
   [Google Scholar]
2. VolčanšekŠ. MuzurovićE. Epicardial adipose tissue modulation: A new horizon for sodium-glucose cotransporter 2 inhibitors.Curr. Vasc. Pharmacol.202131610.2174/0115701611393796250313063902 40114568
   [Google Scholar]
3. TheofilisP. SagrisM. OikonomouE. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes.Diabetes Res. Clin. Pract.202218810992710.1016/j.diabres.2022.109927 35577035
   [Google Scholar]
4. WangW. GaoY. WangJ. Prognostic value of epicardial adipose tissue in heart failure with mid‐range and preserved ejection fraction: A multicenter study.J. Am. Heart Assoc.2024132403678910.1161/JAHA.124.036789 39673347
   [Google Scholar]
5. Ong LopezA.M.C. PajimnaJ.A.T. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: An updated systematic review and meta-analysis.Sci. Rep.2024141212210.1038/s41598‑024‑52603‑5 38267513
   [Google Scholar]
6. CerneaS. OnișorD. RoibanA.L. BenedekT. RatN. Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes.World J. Cardiol.2024161058059410.4330/wjc.v16.i10.580 39492975
   [Google Scholar]
7. TheofilisP. OikonomouE. KarakasisP. FGF21 Analogues in patients with metabolic diseases: Systematic review and meta‐analysis of randomised controlled trials.Liver Int.20254537001610.1111/liv.70016 39898512
   [Google Scholar]